Spotlight On... What are the big events to look for next year?; Teva is recalling blood pressure med; AAIPharma expands facility; and more...

Novartis' ($NVS) Sandoz unit was the first to get a biosimilar approved in the U.S. with Zarxio, its copy of Amgen's ($AMGN) Neupogen, setting off what will be a significant development for the U.S. market as more copies of expensive biologics test the market. Many companies have built facilities with biosimilars in mind. But there were other significant events in 2015, huge M&A deals, and the ongoing uproar from consumers, payers, physicians and lawmakers over how drugmakers have been testing the limits drug pricing. Read about all of the most important developments of the year in FiercePharma. Report

> Teva ($TEVA) is recalling 3,536 bottles of its generic of irbesartan and Hydrochlorothiazide tablets, a generic of Bristol-Myers Squibb's ($BMY) blood pressure medication Avalide over labeling problems. Report

> North Carolina-based AAIPharma Services Corp./Cambridge Major Laboratories, Inc. says it has added new capabilities and capacity for oral solid manufacturing at its Wilmington, NC, facility. Release

> Codexis has extended its deal with Merck & Co. ($MRK) to supply a proprietary enzyme used in the manufacturing process for sitagliptin, the API in Merck's diabetes drug Januvia. Release

Suggested Articles

CureVac and Tesla are teaming up to produce the German vaccine maker's molecular RNA printers, Tesla CEO Elon Musk tweeted Thursday.

The FDA knocked a California compounding pharmacy facility for a suite of sanitary concerns, including the presence of ants in the plant.

Merck Animal Health will plow $100 million into its DeSoto, Kansas, plant to scale up production of animal vaccines.